How Things can go wrong prior to IMP Application
- Deviation of transport and storage conditions
- Labelling issues
- Comparator sourcing
Interface between GMP and GCP
- Clinical Trial Ph I – III
- Interaction and Communication between sponsor and manufacturer / QP
- Investigator initiated Trials
- Early access program
- Compassionate use
Legislation related to Investigational Medicinal Products (IMPs)
- Legislation impacting IMP QPs
- New & upcoming regulations and guidance
- Other topics – within and outside the EU
Q&A Session 1
Packaging and Labelling of IMPs
- Blinding aspects in packaging
- Packaging Technology
- Unblinding risks during packaging
- Just-in-time labelling
- Relabeling
- Reconstitution
Distribution of IMP Supplies
- Distribution concept and prerequisites
- IRT
- Temperature controlled shipments
- Temperature deviations
- Site Transfer
- Depots
- Customs
Challenges of Clinical Trial Material Supply
- Supply Chain planning
- Comparators: selection, procurement, Pedigree
- Blinding
- NIMPs
- Shelf-life assignment
- Outsourcing
Q&A Session 2
Programme Day 2
GCP/GMP Inspections
- The inspection and monitoring process
- Typical and recurrent compliance issues (regarding IMPs)
- Typical issues at the interfaces
- Inspections in Europe and beyond
The Role of the QP in Clinical Trials
- QP Declaration (QPD)
- QP Obligations derived from the “new Annex 13” (C(2017) 8179 final)/ Annex 16, Annex 21 and Clinical Trials Regulation (EU) No 536/2014
- Differences between ATMPs and non-ATMPs
Case Study: QP Tasks and Challenges in Clinical Trials
Q&A Session 3
GCP Aspects to Consider for IMPs
- Roles and responsibilities: sponsor, CRA, Investigator
- ICH GCP
- Storage of IMPs
- Reconstitution
- Accountability and Reconciliation
- Sponsor: Achieving and maintaining the blind
- IMP return and destruction
- IMP related documentation
GMP-related Quality Technical Agreements
- Legislation
- Contractual partners and QP participation
- Planning/ Concepts
Q&A Session 4
Programme Day 3
Data (and Study) Integrity in Clinical Trials
- Responsibilities of investigator, sponsor, and monitor
- Vendors and contractors of electronic Systems: considerations and pitfalls
- Why do we need an Audit Trail (Review)?
- Inspection findings
Handling IMPs at a Hospital Pharmacy
- The role of the hospital pharmacy: manufacturing, organisation, consultancy
- The interface of manufacturing IMPs at a hospital pharmacy and the daily work
- Investigator-Initiated Trials (IITs)
- FAQs: things you need to consider
- Challenges and problem solving
Case Study on GCP Aspects: Handling IMPs at the Investigator’s Site
A last Case Study: How Things can go wrong
- How would you have reacted?
Q&A Session 5